I

InflaRx NV
D

IFRX

2.43000
USD
0.19
(8.24%)
مفتوح الان
حجم التداول
609
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
143,086,351
أصول ذات صلة
    ALNY
    ALNY
    -7.115
    (-2.90%)
    238.390 USD
    B
    BMRN
    0.315
    (0.48%)
    65.995 USD
    C
    CRSP
    -0.250
    (-0.61%)
    40.470 USD
    E
    EDIT
    -0.04500
    (-3.41%)
    1.27500 USD
    N
    NTLA
    -0.090
    (-0.74%)
    12.100 USD
    Q
    QURE
    0.330
    (1.94%)
    17.380 USD
    REGN
    REGN
    10.20
    (1.45%)
    712.80 USD
    S
    SGMO
    -0.08000
    (-3.21%)
    2.41000 USD
    VRTX
    VRTX
    3.84
    (0.97%)
    400.30 USD
    المزيد
الأخبار المقالات

العنوان: InflaRx NV

القطاع: Healthcare
الصناعة: Biotechnology
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.